Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Consolidated Total International Revenue by Year
Consolidated Total International Revenue ($M) ($M)
Merck Consolidated Total International Revenue: $28,134M in FY2025, down 9.6% from a year earlier.
Latest, FY2025
28,134
Period ended Dec 31, 2025
Change on a year earlier
-9.6%
31,126 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Postgres DB segment_values.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated Total International Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28,134 | -9.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 31,126 | +0.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 30,865 | -3.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 32,077 | +22.1% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 26,279 | +19.8% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 21,930 | +5.9% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 20,701 | -13.6% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 23,949 | +5.5% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 22,698 | +6.4% | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 21,329 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). Merck Consolidated Total International Revenue ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db-geo-nonus-rev
See every metric in the Merck KPI table. Data updated Oct 26, 2026.